Avapritinib: a new tyrosine kinase inhibitor for treatment of advanced gastrointestinal stromal tumors. The literature review and clinical case
We have three drugs for treatment of gastrointestinal stromal tumors (GIST): imatinib, sunitinib and regorafenib. Avapritinib (Ayvakit, BLU-285) is one more drug that was approved in January 2020. Avapritinib is a new selective tyrosine kinase inhibitor of PDGFRA and KIT mutations. Based on NAVIGATO...
Main Authors: | Daria A. Filonenko, Bela M. Medvedeva, Andrey A. Meshcheryakov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IP Habib O.N.
2021-02-01
|
Series: | Современная онкология |
Subjects: | |
Online Access: | https://modernonco.orscience.ru/1815-1434/article/viewFile/61163/44252 |
Similar Items
-
Targeting kinases with precision
by: Alexandra K. Gardino, et al.
Published: (2018-05-01) -
Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor
by: Sebastian Bauer, et al.
Published: (2021-07-01) -
Novel approaches to treating advanced systemic mastocytosis
by: Gilreath JA, et al.
Published: (2019-07-01) -
An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumors
by: Yingchao Sun, et al.
Published: (2022-08-01) -
Avapritinib-induced photo-aggravated cutaneous reaction
by: Farinoosh Dadrass, MS, et al.
Published: (2022-03-01)